Viatris Receives FDA Approval For RYZUMVI To Treat Presbyopia In Adults
Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in
Viatris got permission to sell a new eye medicine for older adults. When companies win FDA approvals, it shows their research worked and they can make money from it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.